Results of Fc-protein fusion technology application for vaccine design against infectious diseases of animals and human

The main criteria for current vaccines design are effectiveness, efficaciousness and safety. Increasing requirements for vaccine safety and purity push forward not only classical vaccine development, but also new generation vaccine technology, including sub-unit, recombinant, anti-idiotypic, DNA vaccines etc. This recombinant technology has already demonstrated its advantage, efficaciousness and safety in a large field of therapeutic and curative drug development for animal and human (S. Khan et al., 2016). In 2011, six novel drugs were created based on the new Fc-fusion protein technology. Most of the newly developed drugs affect receptor-ligand interactions, acting as antagonists by blocking direct receptor binding, i.e. EnbrelÒ (etanercept; Amgen, USA), ZaltrapÒ (aflibercept; Sanofi, France), ArcalystÒ (rilonacept; Regeneron, USA), or as agonists for direct stimulation of receptor function which augment immune response as AmeviveÒ (alefacept, Astellas, USA) does, or decrease immune response as NplateÒ (romiplostim; Amgen, USA) does...